New peer-reviewed publication
15 September 2026

ImmuPharma PLC
("ImmuPharma" or the "Company")
New peer-reviewed publication reports P140 activity in a preclinical MASH model
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, announces the publication of new peer-reviewed research evaluating P140 in a preclinical model of metabolic dysfunction-associated steatohepatitis ("MASH"). The paper, entitled "Restoring lysosomal proteostasis reverses steatohepatitis and fibrosis in experimental MASH", has been published in Pharmacological Research by researchers from CNRS and the University of Strasbourg, including Professor Sylviane Muller, co-inventor of P140.
Key findings
· P140 was evaluated in an established mouse model of advanced MASH characterised by liver inflammation and fibrosis.
· Treatment with P140 reduced steatohepatitis and fibrosis and improved several disease-related histological and biological parameters.
· P140 selectively modified a number of dysregulated lysosomal and autophagy-associated markers, while the scrambled control peptide did not reproduce these effects.
· The study provides further peer-reviewed evidence of the biological activity of P140 beyond its original lupus setting and supports continued investigation across diseases characterised by dysregulated cellular homeostasis and autophagy activity.
The study identified substantial disruption of lysosomal and autophagy-associated pathways in experimental MASH. P140 treatment was associated with selective changes in several abnormal markers and with reduced liver fibrosis and steatohepatitis.
The findings add to the growing body of peer-reviewed research around P140 and broaden understanding of its biological activity across different disease settings.
Professor Sylviane Muller, University of Strasbourg and CNRS, commented: "These results provide important new evidence of the biological activity of P140 in an experimental model of advanced MASH. They further highlight the relationship between lysosomal and autophagy-associated pathways, inflammation and fibrosis, and support continued investigation of P140 across disease settings characterised by dysregulated cellular homeostasis."
Tim McCarthy, Chief Executive Officer of ImmuPharma PLC, commented: "We congratulate Professor Muller and her collaborators on the publication of these important findings. The study adds valuable peer-reviewed evidence to the growing body of research around P140 and further demonstrates the breadth of its biological activity.
We look forward to continuing our work with Professor Muller and our academic collaborators as we advance the development of P140."
The publication is available in Pharmacological Research, Volume 232 (2026), article 108427. doi: 10.1016/j.phrs.2026.108427
|
For further information please contact:
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.
For additional information about ImmuPharma please visit www.immupharma.co.uk.
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE